Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Arthur Radley who wrote (14756)	12/17/2004 5:07:51 PM
From: Biomaven	Respond to of 52153

Selling a royalty interest is probably the right move at this point - they are clearly confident that the stock will move higher. If they were bigger and more sophisticated financially they could do a deal like SEPR did selling converts that rely on their high volatility and match it with a call spread. But realistically they probably aren't big enough to to that. No clue about their recent deal. But their Italian partners really seem to know what they are doing. Peter

To: Arthur Radley who wrote (14756)	12/17/2004 5:34:41 PM
From: Icebrg	Read Replies (1) \| Respond to of 52153

CTIC They have stated that they expect to be able to raise at least 30 mUSD. Which is not very much considering their current burn rate. I don't think the recently announced licensing arrangement is much to "bother" about. The company will either be very rich and famous or completely dead and forgotten before any drug from that product line will have reached its maturity. This will by the way be NovusPharma's second try with the platinum drugs. The first time they didn't succeed. Erik